Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus
The options for pharmacological management of type 2 diabetes mellitus have exploded over the last decade or so. Availability of a variety of new drugs, oral as well as injectable, has made the choice of treatment more complex and challenging. Over a decade or so ago, glycemic (glucometabolic) contr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Journal of Mahatma Gandhi Institute of Medical Sciences |
| Subjects: | |
| Online Access: | http://www.jmgims.co.in/article.asp?issn=0971-9903;year=2020;volume=25;issue=1;spage=11;epage=14;aulast= |
| _version_ | 1829105736224866304 |
|---|---|
| author | Tejal Lathia |
| author_facet | Tejal Lathia |
| author_sort | Tejal Lathia |
| collection | DOAJ |
| description | The options for pharmacological management of type 2 diabetes mellitus have exploded over the last decade or so. Availability of a variety of new drugs, oral as well as injectable, has made the choice of treatment more complex and challenging. Over a decade or so ago, glycemic (glucometabolic) control was the main target of treatment in patients with type 2 diabetes mellitus – usually with metformin, sulfonylureas (SU), thiazolidinediones, and insulin (the traditional quartet). There is conflicting evidence on the cardiovascular (CV) effects of the traditional quartet of drugs. The almost serendipitous benefit of sodium-glucose transporter 2 (SGLT2) inhibitors on CVD and kidney disease in patients with type 2 diabetes mellitus has revolutionized the way we view the treatment of diabetes. . What the physician needs to remember when prescribing this drug is – right patient and right intent. |
| first_indexed | 2024-12-12T06:11:47Z |
| format | Article |
| id | doaj.art-a3d75bb8f3b749e5994fa87a6c35a654 |
| institution | Directory Open Access Journal |
| issn | 0971-9903 |
| language | English |
| last_indexed | 2024-12-12T06:11:47Z |
| publishDate | 2020-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Mahatma Gandhi Institute of Medical Sciences |
| spelling | doaj.art-a3d75bb8f3b749e5994fa87a6c35a6542022-12-22T00:35:08ZengWolters Kluwer Medknow PublicationsJournal of Mahatma Gandhi Institute of Medical Sciences0971-99032020-01-01251111410.4103/jmgims.jmgims_40_19Paradigm shift in the pharmacological treatment of type 2 diabetes mellitusTejal LathiaThe options for pharmacological management of type 2 diabetes mellitus have exploded over the last decade or so. Availability of a variety of new drugs, oral as well as injectable, has made the choice of treatment more complex and challenging. Over a decade or so ago, glycemic (glucometabolic) control was the main target of treatment in patients with type 2 diabetes mellitus – usually with metformin, sulfonylureas (SU), thiazolidinediones, and insulin (the traditional quartet). There is conflicting evidence on the cardiovascular (CV) effects of the traditional quartet of drugs. The almost serendipitous benefit of sodium-glucose transporter 2 (SGLT2) inhibitors on CVD and kidney disease in patients with type 2 diabetes mellitus has revolutionized the way we view the treatment of diabetes. . What the physician needs to remember when prescribing this drug is – right patient and right intent.http://www.jmgims.co.in/article.asp?issn=0971-9903;year=2020;volume=25;issue=1;spage=11;epage=14;aulast=cardiovascular outcome trialsglp1 analogssodium-glucose transporter 2 inhibitors |
| spellingShingle | Tejal Lathia Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus Journal of Mahatma Gandhi Institute of Medical Sciences cardiovascular outcome trials glp1 analogs sodium-glucose transporter 2 inhibitors |
| title | Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus |
| title_full | Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus |
| title_fullStr | Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus |
| title_full_unstemmed | Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus |
| title_short | Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus |
| title_sort | paradigm shift in the pharmacological treatment of type 2 diabetes mellitus |
| topic | cardiovascular outcome trials glp1 analogs sodium-glucose transporter 2 inhibitors |
| url | http://www.jmgims.co.in/article.asp?issn=0971-9903;year=2020;volume=25;issue=1;spage=11;epage=14;aulast= |
| work_keys_str_mv | AT tejallathia paradigmshiftinthepharmacologicaltreatmentoftype2diabetesmellitus |